Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
Cytokinetics, Inc. (CYTK) received a notice under Rule 144 that director B Lynne Parshall plans to sell up to 5,000 shares of common stock. The shares were acquired from the issuer through vesting of restricted stock units during the period from May 15, 2025 through May 14, 2026, and the planned sale will be executed through Morgan Stanley Smith Barney LLC.
CYTOKINETICS INC (CYTK) insider Andrew Callos, EVP and Chief Commercial Officer, exercised 10,000 Non-Qualified Stock Options on 2026-08-31 at an exercise price of $23.26 per share, acquiring 10,000 common shares. On the same date, he sold 10,000 common shares at $70.24 per share, leaving 0 options from this grant outstanding. The filing indicates the transactions were made pursuant to a Rule 10b5-1 trading plan.
CYTOKINETICS INC (CYTK) reported that President & CEO Robert I. Blum exercised options and sold shares in a coordinated transaction under a Rule 10b5-1 trading plan. He exercised 7,500 Non-Qualified Stock Options at an exercise price of $10.60 per share, receiving 7,500 common shares, and on the same date sold 7,500 common shares at $70.24 per share. Following the option exercise, he held 164,245 shares of common stock directly, plus indirect holdings of 2,083 shares in each of two irrevocable trusts.
CYTOKINETICS INC (CYTK) reported that its Phase 3 ACACIA-HCM trial of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy met both dual primary endpoints. At Week 36, aficamten produced statistically significant improvements versus placebo in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and peak oxygen uptake (pVO₂), with treatment effects of 3.0 points (p=0.021) and 0.67 ml/kg/min (p=0.003), respectively. Key secondary endpoints, including NYHA class improvement, composite CPET z-score and NT‑proBNP, also favored aficamten, though left atrial volume index and time to first cardiovascular event did not. Aficamten was generally well-tolerated but showed higher rates of serious adverse events, heart failure events, and LVEF <50% than placebo. Cytokinetics plans to submit a supplemental New Drug Application to the FDA in the fourth quarter of 2026 to expand MYQORZO (aficamten) from obstructive to non-obstructive HCM.
CYTOKINETICS INC (CYTK) executive Fady Ibraham Malik, EVP Research & Development, reported an option exercise-and-sell transaction. On 2026-08-18 he exercised 3,500 non-qualified stock options at an exercise price of $7.80 per share, acquiring 3,500 shares of common stock, and on the same date sold 3,500 common shares at $75.82 per share. Following the option exercise, he held 30,386 options of this grant directly. The transactions were affirmed as made pursuant to a Rule 10b5-1 trading plan.
Cytokinetics, Incorporated received an updated ownership report from Wellington Management Group LLP and related entities, filing Amendment No. 2 to a Schedule 13G for its Common Stock (CUSIP 23282W605) as of 06/30/2026.
Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP collectively report 7,116,724 shares of Cytokinetics common stock as beneficially owned, representing 5.12% of the class. These entities report 0 shares with sole voting or dispositive power, 6,231,890 shares with shared voting power, and 7,116,724 shares with shared dispositive power. The shares are owned of record by clients of various Wellington investment advisers, and no single client is reported to hold more than five percent of the class.
CYTOKINETICS INC President & CEO Robert I. Blum exercised options for 7,500 shares of common stock at an exercise price of $10.60 per share and on the same date sold 7,500 shares at $76.76 per share, under a Rule 10b5-1 trading plan. Following the option exercise, he held 171,745 options directly, plus 2,083 shares of common stock in each of two irrevocable trusts reported as indirect ownership.
Cytokinetics reported Q2 2026 results highlighted by initial MYQORZO sales and a major equity raise. Total revenues were $28.6 million, driven by $25.3 million in MYQORZO net product revenue and $3.3 million in collaboration revenue, with no license or milestone revenues. Net loss widened to $198.8 million, or $1.50 per share, as selling, general and administrative costs increased with the commercial launch.
The company ended June 30, 2026 with approximately $1.7 billion in cash, cash equivalents and investments, compared to $1.1 billion at March 31, 2026, supported by a public offering of 11,338,028 shares at $71.00 per share that generated about $760.1 million in net proceeds. As of quarter end, over 700 healthcare providers had prescribed MYQORZO, approximately 1,500 patients had been dispensed therapy and over 80% of patients on therapy were on paid prescriptions. Cytokinetics announced positive Phase 3 ACACIA-HCM results in non-obstructive hypertrophic cardiomyopathy and plans to file a supplemental NDA in the fourth quarter of 2026, while raising its 2026 GAAP combined R&D and SG&A expense guidance to $860–$890 million.